The Cooper Companies, Inc. (NYSE:COO) Director Michael Kalkstein sold 1,715 shares of the company’s stock in a transaction on Wednesday, April 11th. The stock was sold at an average price of $221.66, for a total value of $380,146.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
The Cooper Companies stock traded up $0.41 during midday trading on Thursday, reaching $221.02. The company’s stock had a trading volume of 411,730 shares, compared to its average volume of 489,238. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.61 and a current ratio of 2.83. The Cooper Companies, Inc. has a 52-week low of $194.55 and a 52-week high of $260.26. The stock has a market cap of $10,948.44, a PE ratio of 22.79, a price-to-earnings-growth ratio of 1.76 and a beta of 0.62.
The Cooper Companies (NYSE:COO) last released its quarterly earnings results on Thursday, March 8th. The medical device company reported $2.79 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.28. The Cooper Companies had a return on equity of 16.90% and a net margin of 7.83%. The company had revenue of $590.00 million during the quarter, compared to analysts’ expectations of $583.07 million. During the same period last year, the business posted $1.93 earnings per share. The firm’s revenue was up 18.2% compared to the same quarter last year. sell-side analysts predict that The Cooper Companies, Inc. will post 11.82 EPS for the current fiscal year.
A number of equities research analysts recently weighed in on COO shares. Stephens restated a “hold” rating and set a $270.00 price objective on shares of The Cooper Companies in a research note on Friday, March 9th. Oppenheimer set a $265.00 price objective on The Cooper Companies and gave the stock a “hold” rating in a research note on Thursday, March 29th. Zacks Investment Research cut The Cooper Companies from a “buy” rating to a “hold” rating in a research note on Monday, January 8th. Jefferies Group restated a “buy” rating and set a $285.00 price objective on shares of The Cooper Companies in a research note on Friday, March 9th. Finally, Goldman Sachs started coverage on The Cooper Companies in a research note on Wednesday, April 4th. They set a “neutral” rating and a $231.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $264.18.
TRADEMARK VIOLATION NOTICE: “The Cooper Companies, Inc. (COO) Director Michael Kalkstein Sells 1,715 Shares” was reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://dakotafinancialnews.com/2018/04/12/the-cooper-companies-inc-coo-director-michael-kalkstein-sells-1715-shares.html.
About The Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Receive News & Ratings for The Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.